Abstract
To evaluate demographic, clinical and laboratory features associated with scleroderma-specific auto-antibodies. Sera of 100 patients with systemic sclerosis (SSc) were analyzed by an indirect immunofluorescence technique with HEp-2 cells as a substrate. Specific ANA such as anti-centromere antibodies (ACA), anti-topoisomerase (TOPO), anti-RNA polymerase III (Pol 3), anti-U3-RNP (U3-RNP), anti-Th/To (Th/To) and anti-PM/Scl (PM/Scl) were detected by line immunoassay and anti-U1-RNP (U1-RNP) by ELISA. Frequency of clinical features associated with a specific antibody group was reported cumulatively over the follow-up period. Frequency of specific clinical features was compared across the two disease subtype including limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) as well as the auto-antibody groups. Ninety-four percent of patients were ANA positive with significant higher skin score, Raynauds and digital ulcer/gangrene. Anti-TOPO was detected in 71 % of all patients, in 90.5 % of dcSSC and in 65.8 % of lcSSc. Anti-TOPO was significantly associated with dcSSc, higher skin score, digital ulcer/gangrene, pulmonary fibrosis, DLCO <70 %. U1-RNP antibody was associated with lower fibrosis in lung. ACA was positive in 7 % of patients and exclusively in those with lcSSc. We did not find association between gender and presence of auto-antibodies. Anti-TOPO antibody had a high prevalence in contrast to low prevalence of ACA antibody. There were no differences in clinical subtypes of the disease in patients with positive anti-TOPO and positive ACA. Differences in prevalence of auto-antibodies are suggestive of further genetic study.
Similar content being viewed by others
References
Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593
Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42
Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR Scleroderma Trial and Research group database. Ann Rheum Dis 66:754–763
Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73:490–494
Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78. doi:10.1186/ar2276
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and patogenesis. J Rheumatol 15:202–205
Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Bountin LTH et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interestial lung disease. Arthritis Rheum 54:181–191
Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, MD, pp 51–64
Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 1173:166–173
Hanke K, Dahnrich C, Bruckner C, Huscher D, Becker M, Janssen A et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11:R28
Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelstssi C, La Montagna G et al (2002) Systemic sclerosis, demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81:139–159
Mayes MD (2003) Scleroderma epidemiology. Rheum Dis Clin North Am 29:239–254
Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755
Solomon DH, Kavanaugh AJ, Schur PH (2002) The American College of Rheumatology Ad Hoc Committee on immunologic testing guidelines evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434–444
Hesselstrand R, Scheja A, Shen GO, Wiik A, Akesson AT (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 42:534–540
Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, Rothfield N (1994) Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 37:248–252
McNeilage LJ, Youngchaiyud U, Whittingham S (1989) Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32(1):54–60
Steen DV, Powell LD, Medsger AT (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203
Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA (1998) African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801–807
Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48:43–51
Stupi AM, Steen VD, Owen GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension (PTH) in the CREST syndrome variant of progressive sclerosis (PSS). Arthritis Rheum 29:515–524
Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 40:1157–1162
Okano Y, Steen VD, Medsger ATA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrilliarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100
Primer G, Steen VD, Penning CA, Medsger T, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis. Arthritis Rheum 31:525
Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83
Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477–484
Chang M, Wang R, Yangco D, Sharp G, Komatireddy G, Hoffman R (1998) Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopath 89:71–78
Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunoassay. Rheumatology 48:1570–1574
Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerase and other autoantibody specification in systemic sclerosis. Br J Rheumatol 37:15–20
Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013
Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP (2009) A longitudinal study of anti-RNA polymerase III antibody level in systemic sclerosis. Rheumatology 48:1218–1221
Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413
Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14(1):111–124
Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S et al (1999) Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 117:383–387
Reveille JD, Solomon DH (2003) American College of Rheumatology, Ad Hoc Committee on immunological testing guidelines evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 15(49):399–412
Dick T, Mierau R, Bartz-Bazzanaella P (2002) Coexistence of antitopoisomeras and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61:121–127
Kuwana M, Kimura K, Hirakata M (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842–846
Acknowledgments
This research has been funded by Tehran University of Medical Sciences., Immunology Research Center.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Poormoghim, H., Moghadam, A.S., Moradi-Lakeh, M. et al. Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 33, 1943–1950 (2013). https://doi.org/10.1007/s00296-013-2668-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-013-2668-5